Latest News

Common multiple sclerosis drugs taken together do not reduce relapse risk

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Autism after high school: Making the transition

  • New technology shows promise for delivery of therapeutics to the brain

  • Higher suicide risk after served prison sentence

  • Major factor in development of Huntington's disease uncovered

  • Neglect of culture in medicine is 'single biggest barrier' to achieving better health

  • Different brain tumors have the same origin, new findings show

  • Politics can interact with evolution to shape human destiny

  • Heavy drinking in adolescence associated with lasting brain changes, animal study suggests

  • From age 8 to 80, expert reveals the price we pay for not sleeping

  • Evolution of competitiveness: Scientists explain diversity in competitiveness

  •